Charles River Partners With Magellan Stem Cells on Viral Safety Testing
Charles River Laboratories International, Inc. (CRL) has entered into a partnership with Magellan Stem Cells to deliver viral safety and release testing services. Under the agreement, Charles River will perform regulated Next-Generation Sequencing safety checks to support Magellan's Zelestrocel program as the treatment moves toward Phase III clinical testing and potential commercial production.
The deal highlights expanding demand for complex biologics and cell and gene therapy services. By providing regulatory-grade testing, Charles River reinforces its presence in higher-margin testing areas while utilizing capabilities gained through its acquisition of PathoQuest. Following the announcement, shares of Charles River were virtually flat, rising 0.02% to $301.90.
Investors will look for additional details regarding contract value and scope, as well as the progress of the Zelestrocel Phase III trials. Continued advancement of the therapy could lead to recurring, higher-volume commercial release testing for Charles River over time.
Key points
- Charles River Laboratories International, Inc. (CRL) partnered with Magellan Stem Cells for viral safety testing.
- Charles River will provide regulated Next-Generation Sequencing and release testing for the Zelestrocel program.
- The agreement supports Magellan's Zelestrocel as it prepares for Phase III clinical trials and potential commercialization.
- The contract utilizes testing capabilities from Charles River's recent acquisition of PathoQuest.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the partnership between Charles River and Magellan Stem Cells?
Charles River Laboratories will provide viral safety and release testing to support Magellan Stem Cells' Zelestrocel program as it advances toward Phase III clinical trials and potential commercialization.
Which therapy program is covered by the Charles River agreement?
The agreement covers Magellan Stem Cells' Zelestrocel program, providing regulatory-grade testing services for its upcoming Phase III trials.
How does this deal benefit Charles River Laboratories?
The partnership expands Charles River's footprint in cell and gene therapy testing and leverages capabilities from its PathoQuest acquisition to support higher-margin biologics services.